Back to Search
Start Over
CO 2 The impact of clinical and genetic findings on the management of young Brugada syndrome patients
- Source :
- Archives of Cardiovascular Diseases Supplements, Archives of Cardiovascular Diseases Supplements, Elsevier/French Society of Cardiology, 2015, 12e congrès médico chirurgical de la FCPC & 5es rencontres francophones multidisciplinaires des cardiopathies congénitales, 7 (4), pp.259. ⟨10.1016/S1878-6480(15)30296-2⟩, Archives of Cardiovascular Diseases Supplements, Elsevier/French Society of Cardiology, 2015, 12e congrès médico chirurgical de la FCPC & 5es rencontres francophones multidisciplinaires des cardiopathies congénitales, 7 (4), pp.259. 〈10.1016/S1878-6480(15)30296-2〉, Archives of Cardiovascular Diseases Supplements, 2015, 12e congrès médico chirurgical de la FCPC & 5es rencontres francophones multidisciplinaires des cardiopathies congénitales, 7 (4), pp.259. ⟨10.1016/S1878-6480(15)30296-2⟩
- Publication Year :
- 2015
- Publisher :
- Elsevier BV, 2015.
-
Abstract
- International audience; Aims - Brugada Syndrome (BrS) is an arrhythmogenic disease associated with sudden cardiac death (SCD) which seldom manifests and is recognized in childhood. We aim to describe the pediatric BrS clinical presentation to identify prognostic factors for risk stratification, and to propose a data-based approach management. Methods and results - We studied 106 patients, under 19 years of age at diagnosis with spontaneous (n=36) or drug-induced (n=70) BrS from 16 European hospitals. At diagnosis, mean age was 11.1±5.7 years and most patients were asymptomatic [family screening (n=67), incidental (n=13)] while 15 had experienced syncope, 6 aborted SCD or symptomatic ventricular tachycardia, 2 supraventricular tachycardia (SVT), 3 palpitations or presyncope. During follow-up (median: 54 months), 10 patients had life-threatening arrhythmias (LTA) including 3 deaths. Six experienced syncope and 4 SVT. Fever triggered 27% of LTA events. An ICD was implanted in 22 with major adverse events in 41%. Of the 11 patients treated with hydroquinidine, 8 remained asymptomatic. Genetic testing was performed in 75 patients and SCN5A rare variants were identified in 58; among the 32 pediatric probands tested 15 were genotype positive. Of the 10 patients with LTA the 9 with genetic testing were all genotype positive whereas the 17 SCN5A negative patients remained asymptomatic. Spontaneous BrS type 1 ECG (p=0.005) and symptoms at diagnosis (p=0.0015) were predictors of lta. Time to the first LTA event was shorter in patients with both symptoms at diagnosis and spontaneous BrS type 1 ECG pattern (p=0.01) (figure 1). Conclusions - Spontaneous type 1 ECG and symptoms at diagnosis are predictors of LTA events in the young affected by BrS. The management of BrS should become age-specific and prevention of SCD may involve genetic testing, aggressive use of anti-pyretics and quinidine with risk-specific consideration for the ICD
- Subjects :
- medicine.medical_specialty
030204 cardiovascular system & hematology
Ventricular tachycardia
Asymptomatic
Sudden cardiac death
03 medical and health sciences
0302 clinical medicine
Internal medicine
medicine
Palpitations
[ SDV.IB ] Life Sciences [q-bio]/Bioengineering
cardiovascular diseases
030304 developmental biology
Genetic testing
Brugada syndrome
0303 health sciences
Presyncope
medicine.diagnostic_test
business.industry
medicine.disease
3. Good health
Cardiology
[SDV.IB]Life Sciences [q-bio]/Bioengineering
Supraventricular tachycardia
medicine.symptom
business
Cardiology and Cardiovascular Medicine
Subjects
Details
- ISSN :
- 18786480
- Volume :
- 7
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Archives of Cardiovascular Diseases Supplements
- Accession number :
- edsair.doi.dedup.....c2e7d5c3e49bd69ddf7ee5f7c531c325
- Full Text :
- https://doi.org/10.1016/s1878-6480(15)30296-2